Fluicell is developing next-generation tissue-based solutions for regenerative medicine and drug development, targeting serious disease. Our product portfolio consists of our therapeutic solution for type 1 diabetes, based on engineered pancreatic islets. We are also conducting development of human cardiac and kidney tissue models for drug screening applications.
Our product development is powered by our universal tissue production platform Nexocyte that enables us to create detailed functional tissues for therapeutic or drug screening use. The platform is compatible with any cell type and can be applied to any disease area. When it comes to achieving the next breakthrough in regenerative medicine and drug development, we are always looking for innovative partnerships to advance our ongoing development or to create new collaborations.
Type 1 diabetes tissue therapeutics
Fluicell develops engineered islets aimed at achieving complete replacement of the endocrine function of the islets of Langerhans that is missing in patients with type 1 diabetes. Fluicell’s therapeutic concept uses the Biopixlar technology to create immune system-protected islets with a controlled size, shape and composition, and with the ability for both insulin and glucagon secretion. Our islets provide a path toward a curative solution for type 1 diabetes without the reliance on scarce donor materials.
Tissue-based cardiac models
Fluicell develops bioprinted models for cardiac safety screening in collaboration with a pharmaceutical industry partner. The developed models aim at providing human-relevant predictive data on cardiac toxicity that enables strategic decision-making early in the drug development process. The screening models are created using Biopixlar and consists of multiple cell types, arranged in great detail in a way that mimics native cardiac tissue.
Multifunctional kidney models
Fluicell develops an advanced microphysiological model of humanized kidney tubulointerstitium for drug testing and kidney disease modeling. The model combines Fluicell’s high-precision bioprinting capacity with microphysiological systems technology to create an advanced kidney model that accurately replicates kidney function and disease mechanisms. Model development is carried out through the EU-funded BIRDIE consortium, which also includes Maastricht University, Nantes University and TissUse GmbH.